Cevostamab

DRUG11 trials

Conditions

Multiple MyelomaMultiple Myeloma (MM)Relapsed or Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma

Phase 1

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Start: 2017-09-19End: 2026-01-07Updated: 2026-02-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Active, not recruitingNCT04910568

Genentech, Inc.Multiple Myeloma

Start: 2021-07-26End: 2029-12-10Updated: 2026-03-19

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

RecruitingNCT05137054

Regeneron PharmaceuticalsMultiple Myeloma

Start: 2022-08-17End: 2034-09-26Target: 317Updated: 2026-01-22

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruitingNCT05535244

Hoffmann-La RocheMultiple Myeloma

Start: 2022-10-17End: 2027-02-26Target: 90Updated: 2026-02-09

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

RecruitingNCT05583617

Hoffmann-La RocheMultiple Myeloma

Start: 2023-11-14End: 2028-07-31Target: 200Updated: 2026-04-03

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruitingNCT05646836

Genentech, Inc.Multiple Myeloma

Start: 2023-03-21End: 2026-11-18Target: 90Updated: 2026-02-17

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

RecruitingNCT05927571

Genentech, Inc.Relapsed or Refractory Multiple Myeloma

Start: 2023-08-10End: 2027-07-31Target: 120Updated: 2026-04-02

A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma

Active, not recruitingCTIS2023-505865-94-00

F. Hoffmann-La Roche AGRelapsed/Refractory Multiple Myeloma

Start: 2022-10-26Target: 38Updated: 2025-12-10

CO43923 Master Protocol: A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substudy 1: A Non-Interventional Study to Collect Patient-Level Data in Patients with Multiple Myeloma CO43923 Substudy 2 Cevos + Len Treatment: A Phase Ib, Single Arm, Open-Label Study Evaluating the Safety and Efficacy of Cevostamab in Combination with Lenalidomide in Patients with Cytogenetic High-Risk Features Receiving Maintenance Treatment After First Response from Multiple Myeloma Post-Stem Cell Transplant CO43923 Substudy 4 Cevostamab+ Iberdomide Treatment: A Phase Ib, Single Arm, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Combination with Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

RecruitingCTIS2023-504484-16-00

F. Hoffmann-La Roche AGMultiple Myeloma (MM)

Start: 2022-11-18Target: 32Updated: 2025-10-20

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

RecruitingNCT06934044

Hoffmann-La RocheMultiple Myeloma

Start: 2025-05-13End: 2028-11-04Target: 20Updated: 2026-03-16

Phase 2

Cevostamab Following CAR T Cell Therapy for RRMM

Active, not recruitingNCT05801939

University of PennsylvaniaRelapsed/Refractory Multiple Myeloma

Start: 2023-07-11End: 2028-05-31Target: 30Updated: 2025-12-18

Blood2025-11-03

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Blood2025-11-03

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Blood2025-11-03

Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.

Journal of Clinical Oncology2025-05-282 citations

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.

Journal of Clinical Oncology2025-05-28

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Blood2024-11-0518 citations

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Blood2024-11-053 citations

Quantitative Pharmacology for Dose and Regimen Determination of Cevostamab Monotherapy in Relapsed/Refractory Multiple Myeloma

Blood2024-11-05

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Blood2023-11-0210 citations

High Dimensional Profiling of Patient-Derived Multiple Myeloma Bone Marrow Specimens Treated with an FcRH5-Targeted Bispecific Ex Vivo

Blood2023-11-02

Integrative Analysis of the Tumor and Microenvironment to Model the Molecular Heterogeneity Underlying the Response to Cevostamab in Relapsed/Refractory Multiple Myeloma

Blood2023-11-02

Evaluation of Immune Reconstitution in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Cevostamab in Phase I Study GO39775

Blood2023-11-02

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB

HemaSphere2023-08-014 citations

CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.

Journal of Clinical Oncology2023-06-0138 citations

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Blood2022-11-1571 citations

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Blood2022-11-1538 citations

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Blood2022-11-157 citations

CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.

Journal of Clinical Oncology2022-06-017 citations

PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

HemaSphere2022-06-011 citations

P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB

HemaSphere2022-06-01

4 more papers not shown

Cevostamab

Sponsors

Conditions

Phase 1

Phase 2

Related Papers